Nevertheless, recent evidence indicates that blood NfL may perform well as a surrogate endpoint of response to antisense oligonucleotides (ASOs) therapy in a prion disease mouse model (Minikel et al., 2020), where a significant reduction of the biomarker level was documented after drug administration. The gene discussed is NEFL; the disease is prion disease.